Skip to main content

2019 | Lymphödem | OriginalPaper | Buchkapitel

17. Lymphödem

verfasst von : Sarah L. Fründt, Cornelia Liedtke, Thorsten Kühn, Michael Untch

Erschienen in: Praxisbuch Gynäkologische Onkologie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Die häufigste Ursache eines Lymphödems der oberen Extremität ist die Behandlung eines Mammakarzinoms durch axillare Operation oder Bestrahlung. Die Inzidenz des Lymphödems korreliert dabei mit der Anzahl entfernter Lymphknoten, ist aber auch abhängig von patienten- und tumorassoziierten Eigenschaften. Durch die Sentinel-Lymphknoten-Entfernung, die heute bei klinisch nodal-negativen Patientinnen standardmäßig durchgeführt wird, ist es bereits zu einer deutlichen Reduktion von Lymphödemen des Armes gekommen. Anhand von klinischen Studien wird weiter untersucht, bei welchen Patientinnen auch bei Lymphknotenbefall schonender vorgegangen werden kann und wo auf eine Axilladissektion verzichtet werden kann. Bei bestehendem Lymphödem ist die frühzeitige Diagnose und Therapie entscheidend für die Lebensqualität der Patientin.
Literatur
Zurück zum Zitat Abu-Rustum NR, Gemignani ML, Moore K et al (2003) Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot-data and comparison to laparotomy. Gynecol Oncol 91:402–409CrossRef Abu-Rustum NR, Gemignani ML, Moore K et al (2003) Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot-data and comparison to laparotomy. Gynecol Oncol 91:402–409CrossRef
Zurück zum Zitat ASTEC study group, Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. The Lancet 373(9658): 125–136 ASTEC study group, Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. The Lancet 373(9658): 125–136
Zurück zum Zitat Biglia N, Zanfagnini V, Daniele A et al (2017) Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 37(8):4005–4015PubMed Biglia N, Zanfagnini V, Daniele A et al (2017) Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 37(8):4005–4015PubMed
Zurück zum Zitat Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after eboadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC Study. J Clin Oncol 33(3):258–264CrossRef Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after eboadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC Study. J Clin Oncol 33(3):258–264CrossRef
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455–1461CrossRef Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455–1461CrossRef
Zurück zum Zitat Caudle A, Yang W, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072–1078CrossRef Caudle A, Yang W, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072–1078CrossRef
Zurück zum Zitat Cibula D, Oonk MH, Abu-Rustum NR et al (2015) Sentinel lymph node biopsy in the management of gynecologic cancer. Curr Opin Obstet Gynecol 27(1):66–72CrossRef Cibula D, Oonk MH, Abu-Rustum NR et al (2015) Sentinel lymph node biopsy in the management of gynecologic cancer. Curr Opin Obstet Gynecol 27(1):66–72CrossRef
Zurück zum Zitat Classe JM, Campion L, Alran S et al (2014) Sentinel node surgery after neoadjuvant chemotherapy in patient with axillary node involvment: the French GANEA 2 prospective multi-institutional trial. San Antonio 2014 P2-01-01 Classe JM, Campion L, Alran S et al (2014) Sentinel node surgery after neoadjuvant chemotherapy in patient with axillary node involvment: the French GANEA 2 prospective multi-institutional trial. San Antonio 2014 P2-01-01
Zurück zum Zitat Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel in breast cancer (EORTC 10981-22023 AMAROS): a randomized, mulicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRef Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel in breast cancer (EORTC 10981-22023 AMAROS): a randomized, mulicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRef
Zurück zum Zitat Frost JA, Webster KE, Bryant A et al (2015) Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev, September 21(9): CD007585 Frost JA, Webster KE, Bryant A et al (2015) Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev, September 21(9): CD007585
Zurück zum Zitat Galimberti V, Kahler Ribeiro Fontana S, Maisonneuve P et al (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42(3):361–368CrossRef Galimberti V, Kahler Ribeiro Fontana S, Maisonneuve P et al (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42(3):361–368CrossRef
Zurück zum Zitat Gartner R, Jensen MB, Kronborg L et al (2010) Self-reported arm-lymphedema and functional impairment after breast cancer treatment–a nationwide study of prevalence and associated factors. Breast 19:506–515CrossRef Gartner R, Jensen MB, Kronborg L et al (2010) Self-reported arm-lymphedema and functional impairment after breast cancer treatment–a nationwide study of prevalence and associated factors. Breast 19:506–515CrossRef
Zurück zum Zitat Garza III R, Skoracki R, Hock K (2017) A comprehensive overview of the surgical management od secondary lymphedema of the upper and lower extremeties related to prior oncologic therapies. BMC Cancer 17(1):468 Garza III R, Skoracki R, Hock K (2017) A comprehensive overview of the surgical management od secondary lymphedema of the upper and lower extremeties related to prior oncologic therapies. BMC Cancer 17(1):468
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575CrossRef Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575CrossRef
Zurück zum Zitat Hayes S, Cornish B, Newman B (2005) Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat 89:221–226CrossRef Hayes S, Cornish B, Newman B (2005) Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat 89:221–226CrossRef
Zurück zum Zitat Holloway RW, Abu-Rustum NR, Bakces FJ (2017) Sentinel lymph node mapping and staging in endometrial cancer: a society of gynecologic oncology literature review with consensus recommendations. Gynecol Oncol 146(2):405–415CrossRef Holloway RW, Abu-Rustum NR, Bakces FJ (2017) Sentinel lymph node mapping and staging in endometrial cancer: a society of gynecologic oncology literature review with consensus recommendations. Gynecol Oncol 146(2):405–415CrossRef
Zurück zum Zitat Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet 14:609–618CrossRef Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet 14:609–618CrossRef
Zurück zum Zitat Lécuru F, Mathevet P, Querleu D et al (2011) Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol May1, 29(13): 1686–1691CrossRef Lécuru F, Mathevet P, Querleu D et al (2011) Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol May1, 29(13): 1686–1691CrossRef
Zurück zum Zitat Panici PB, Baile S, Maneschi F (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef Panici PB, Baile S, Maneschi F (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef
Zurück zum Zitat Panici PB, Maggioni A, Hacker N (2005) Systemic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97(8):560–566CrossRef Panici PB, Maggioni A, Hacker N (2005) Systemic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97(8):560–566CrossRef
Zurück zum Zitat Reimer T, Stachs A, Nekljudiva V (2017) Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c/iT1-2) in the context of breast conserving therapy: first results following commencement of the Intergroup-Sentinel-Mamma (INSEMA) trial. Geburtshilfe und Frauenheilkunde77(2): 149CrossRef Reimer T, Stachs A, Nekljudiva V (2017) Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c/iT1-2) in the context of breast conserving therapy: first results following commencement of the Intergroup-Sentinel-Mamma (INSEMA) trial. Geburtshilfe und Frauenheilkunde77(2): 149CrossRef
Zurück zum Zitat Soliman PT et al (2017) A prospective validation study of sentinel lymph node mapping for high-risk endometrium cancer. Gynecol Oncol 146(2):234–239CrossRef Soliman PT et al (2017) A prospective validation study of sentinel lymph node mapping for high-risk endometrium cancer. Gynecol Oncol 146(2):234–239CrossRef
Zurück zum Zitat Wojcinski S, Nuengsri S, Hillemanns P et al (2012) Axillary dissection in primary breast cancer: variations of the surgical technique and influence on morbidity. Cancer Manag Res 4:121–127CrossRef Wojcinski S, Nuengsri S, Hillemanns P et al (2012) Axillary dissection in primary breast cancer: variations of the surgical technique and influence on morbidity. Cancer Manag Res 4:121–127CrossRef
Metadaten
Titel
Lymphödem
verfasst von
Sarah L. Fründt
Cornelia Liedtke
Thorsten Kühn
Michael Untch
Copyright-Jahr
2019
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-57430-0_17

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.